Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy: A Randomized Clinical Trial.
A monoclonal antibody proved safer and more effective than oral immunotherapy for multi-food allergy, though both are now FDA-approved options for shared decision-making.
This double-blind RCT from the NIAID-funded OUTMATCH program compared omalizumab monotherapy to multiallergen OIT in 117 participants with allergy to peanuts and at least two other foods (ages 1-55 years, 10 US academic centers). Omalizumab showed superior ITT treatment success (36% vs 19%), but the advantage was substantially driven by MOIT's 31% serious adverse event rate and 22% discontinuation rate versus 0% for omalizumab—important context for shared decision-making between these two FDA-approved treatment modalities.
What the study was
- Study design
- double_blind_randomized_controlled_trial
- Population
- Multifood-allergic participants (peanut plus >=2 other foods), ages 1-55 years, 10 US academic centres (n=117)
- Sample size
- 117
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- JAMA Pediatr
Why it surfaced
JAMA Pediatr RCT providing head-to-head evidence for omalizumab vs MOIT in multifood allergy, revealing that omalizumab's ITT superiority is largely a safety-driven effect from MOIT discontinuations—directly informs clinical decision-making and future trial design for multifood allergy desensitization.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.